Accepted for/Published in: JMIR AI
Date Submitted: Sep 24, 2022
Open Peer Review Period: Sep 24, 2022 - Nov 19, 2022
Date Accepted: Dec 28, 2022
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Artificial Intelligence algorithms in healthcare: Is current FDA regulation sufficient?
ABSTRACT
Given the growing use of machine learning (ML) technologies in healthcare, regulatory bodies face unique challenges in governing their clinical use. Under the regulatory framework of the Food and Drug Administration Agency (FDA), approved ML algorithms are practically ‘locked’, preventing their adaptation in the ever-changing clinical environment, defeating the unique trait of ML technology in learning from real-world feedback. At the same time, regulations must enforce a strict level of patient safety in order to mitigate risk at a systemic level. Given that ML algorithms often support, or at times replace the role of medical professionals, we have proposed a novel regulatory pathway analogous to the regulation of medical professionals, encompassing the lifecycle of an algorithm from inception, development to clinical implementation and continual clinical evaluation. We then discuss in-depth technical and non-technical challenges to its implementation, and offer potential solutions in order to unleash the full potential of ML technology in healthcare, while ensuring quality, equity and safety.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.